+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the drug WS016 to treat hyperkalemia, a condition characterized by high potassium levels in the blood. This open-label Phase 3 clinical trial includes two phases a corrective phase aiming to reduce potassium levels within 24 to 72 hours, followed by a maintenance phase to keep potassium levels normal over a 12-month period in participants who meet specific criteria after the first phase. Participants first receive oral doses of WS016 12 grams three times daily during the corrective phase. Those whose potassium levels normalize enter the maintenance phase, receiving WS016 once daily at 12 grams, with dose adjustments based on potassium levels over the following 12 months. This study evaluates the long-term safety and effectiveness of WS016 in maintaining normal potassium levels. Throughout the study, participants undergo regular blood tests to monitor potassium levels and safety assessments during both phases. Researchers measure the percentage of participants maintaining potassium at or below 5.0 mmolL during the maintenance phase. Adverse events and changes in potassium are tracked closely. The total participation may last over a year, including both treatment phases and follow-up assessments.

Age: 18Years +All GendersPhase 3
50 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations
M

Actively Recruiting

This trial investigates the effects of different durations of fasting after esophageal variceal ligation therapy in patients with cirrhosis and portal hypertension. Researchers aim to compare early postoperative oral intake with a 6-hour fasting period against delayed oral intake with fasting periods of 24 or 48 hours. The study evaluates the safety and effectiveness of these approaches in reducing early postoperative rebleeding. Participants are randomly assigned to one of three groups with varying fasting durations after ligation surgery 6 hours, 24 hours, or 48 hours. The 6-hour fasting group begins with a liquid diet during the first day after surgery, progressing to semi-liquid or soft diets by days 4-7, and regular diets starting day 8. The groups fasting 24 or 48 hours receive intravenous fluids during fasting, followed by gradual diet progression similar to the 6-hour group. This study is conducted across multiple centers and uses a quadruple-blind design. During the study, participants will be monitored for early rebleeding events over 6 weeks, with additional assessments of hospital stay length, nutritional status, and non-bleeding adverse events over 4 weeks. Researchers will track diet tolerance and complications through scheduled visits and evaluations. The study runs from June 2026 to June 2027, with careful safety and outcome monitoring to understand the impact of fasting duration on recovery after variceal ligation.

Age: 18Years +All GendersPhase Not Applicable
12 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.

Age: 18Years +All GendersPhase 3
131 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of Antiwei granules for treating the common cold, specifically the wind-cold syndrome. This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial sponsored by Tasly Pharmaceutical Group Co., Ltd. It aims to assess how well Antiwei granules work and how safe they are in adults aged 18 to 65 with recent onset of common cold symptoms. Participants will be randomly assigned to receive either Antiwei granules or a matching placebo. The treatment involves taking one sachet of granules 6 grams orally three times a day, for three days. Both groups follow the same dosing schedule, taking nine sachets total. The study compares outcomes between the Antiwei granule group and the placebo group over this short treatment period. Throughout the trial, participants will be closely monitored with assessments focusing on the cure rate after three days of treatment. Researchers will also track symptom recovery time, remission rate, disappearance of individual symptoms, traditional Chinese medicine syndrome efficacy, changes in symptom severity, occurrence of complications, emergency medication use, and overall cure of cough and cold symptoms. The total participation time includes the three-day treatment and monitoring period to evaluate treatment effects and safety.

Age: 18Years - 65YearsAll GendersPhase 3
24 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effectiveness of a single dose of baloxavir marboxil compared with a placebo for preventing influenza virus infection in people who live with someone diagnosed with influenza. This study focuses on household contacts of influenza patients and aims to reduce symptomatic, laboratory-confirmed influenza cases. It is a Phase III, randomized, double-blind, placebo-controlled trial involving participants aged 5 years and older. Participants who live with an influenza patient will receive either baloxavir marboxil or a matching placebo based on their body weight. The influenza patients themselves will not receive the study drug but will continue their usual standard of care treatment. The study uses a parallel design to compare outcomes between these groups during the prevention period. Throughout the study, participants will be monitored from Day 1 up to Day 10 for influenza infection confirmed by laboratory tests and symptoms such as fever and respiratory issues. Researchers will also track adverse events for up to 21 days. Participants will keep symptom diaries if age-appropriate, and COVID-19 testing will be performed to exclude those with infection. The study completion is expected by April 2027.

Age: 5Years +All GendersPhase 3
8 locations
E

Actively Recruiting

Researchers are studying adult patients who have had an acute ischemic stroke caused by blockage in medium-sized brain blood vessels. This trial aims to evaluate the effectiveness and safety of tenecteplase compared to standard medical care in patients treated within 4.5 to 24 hours after stroke symptoms begin. The study focuses on a specific group with confirmed medium vessel occlusions and uses imaging methods to select participants based on brain blood flow and damage. Participants will be randomly assigned to receive either a single intravenous dose of tenecteplase 0.25 mg per kilogram, up to 25 mg or standard medical treatment, which may include aspirin andor clopidogrel, following national stroke care guidelines. Treatments will be given between 4.5 and 24 hours after the patient was last seen well. The trial is controlled, randomized, and open-label with blinded evaluation of outcomes. During the study, participants will be monitored through clinical assessments including the National Institutes of Health Stroke Scale and the modified Rankin scale to measure disability at 90 days. Imaging tests such as CT or MRI perfusion scans will be used to evaluate brain blood flow and damage. Researchers will track neurological improvement, adverse events, bleeding events, and quality of life up to one year after treatment. The main outcome is the proportion of patients achieving minimal disability at 90 days post-treatment.

Age: 18Years +All GendersPhase 3
7 locations
C

Actively Recruiting

Researchers are evaluating the long-term effectiveness and safety of drug-coated balloon DCB strategies, including DCB alone or combined with drug-eluting stents DES, compared to DES-only treatment in patients with chronic total occlusion CTO of coronary arteries after successful reopening. This multicenter randomized controlled trial aims to fill the gap in direct comparative data between DCB and DES treatments for CTO, with the goal of optimizing treatment strategies, reducing stent use, lowering complication risks, and improving patient outcomes. Participants will be randomly assigned to either the DCB group, which involves balloon angioplasty with drug coating and possible provisional DES implantation if needed hybrid strategy, or the DES-only group receiving standard drug-eluting stent placement. Both groups receive standard medical therapy including at least 12 months of dual antiplatelet therapy DAPT. The study includes a 9-month primary endpoint assessment and a 36-month follow-up period to monitor long-term outcomes. During the study, patients will undergo angiographic evaluation for late lumen loss at 9 months, assessed by an independent laboratory using quantitative coronary angiography. Clinical events such as target lesion failure, cardiac death, myocardial infarction, and repeat revascularization will be monitored up to 36 months. Patient-reported outcomes like angina status and quality of life, as well as intravascular imaging and safety parameters, will also be collected. Overall participation spans over three years with regular follow-up visits to assess treatment effects and safety.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
18 locations
E

Actively Recruiting

Stroke is one of the leading causes of death worldwide, with ischemic stroke being the most common type. Researchers are evaluating whether early administration of oral aspirin after intravenous thrombolysis improves functional outcomes for patients with acute ischemic stroke. The study aims to determine if starting aspirin treatment within 3 hours of thrombolysis can prevent neurological deterioration without increasing bleeding risks. Participants are randomly assigned to one of two groups the interventional group receives 300 mg of oral aspirin shortly after starting intravenous thrombolysis, while the control group receives a placebo. Both groups receive the best standard medical care according to current guidelines. Aspirin tablets may be chewed or given via a nasogastric tube if swallowing is difficult. The treatment is administered within 3 hours of initiating thrombolysis. During the study, participants are monitored for neurological improvements and potential complications using scales like the modified Rankin scale and NIH Stroke Scale at various time points up to 90 days after stroke. Researchers will assess functional outcomes, neurological changes, and safety measures, including the risk of intracranial hemorrhage. The total follow-up period extends to 90 days post-stroke.

Age: 18Years +All GendersPhase 3
119 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.

Age: 18Years - 80YearsAll GendersPhase 3
41 locations

1-10 of 19

1